Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 331 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pelvic Neoplasm Clear all

Conditions: Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions: Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 85 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Patients With Lung, Breast, Head and Neck, or Pelvic Malignancies
Interventions: Survey; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endometrial Cancer
Interventions: Hypofractionated Radiation, Clinical Follow-Up and Assessments; Radiation · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more

Conditions: Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
Interventions: capecitabine, brachytherapy, radiation therapy; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Bladder Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Transitional Cell Carcinoma of the Bladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions: gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis, pharmacological study, cisplatin; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 3
States / cities: Boston, Massachusetts • Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Therapy-related Toxicity
Interventions: triapine, cisplatin, external beam radiation therapy, quality-of-life assessment, questionnaire administration, fludeoxyglucose F 18, positron emission tomography, computed tomography; Drug · Radiation · Procedure + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage I Cervical Cancer AJCC v6 and v7, Stage IA Cervical Cancer AJCC v6 and v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7
Interventions: Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration; Drug · Radiation · Other
Lead sponsor: GOG Foundation; Network
Eligibility: 18 Years and older · Female only
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 698
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 433 more

Conditions: Liver Metastasis, Pelvic Cancer, Head and Neck Cancer, Sarcoma, Rectal Cancer, Breast Cancer, Colorectal Cancer, Mouth Cancer
Interventions: LS 11(Taporfin Sodium), Lumaflex Light Delivery Catheter; Drug · Device
Lead sponsor: Light Sciences LLC; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 6
States / cities: Tucson, Arizona • Detroit, Michigan • Greenville, North Carolina + 2 more

Conditions: Anemia
Interventions: Epoetin Alfa group, Placebo group; Drug · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Gainesville, Florida

Conditions: Gynaecologic Cancer, Cervical Cancer, Radiation Therapy
Interventions: Volume Modulated Arc Therapy (VMAT), Intensity Modulated Proton Therapy (IMPT); Radiation
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older · Female only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 5
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more

Conditions: Surgery
Interventions: Educational Module, Salpingectomy; Behavioral · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 45 Years and older · Female only
Enrollment: 266 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Baltimore, Maryland • Boston, Massachusetts • Basking Ridge, New Jersey + 7 more

Conditions: Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
Interventions: PRN1371; Drug
Lead sponsor: Principia Biopharma, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: San Francisco, California • Baltimore, Maryland • Winston-Salem, North Carolina + 2 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions: Gemcitabine Hydrochloride, Cisplatin, Radiation Therapy, Internal Radiation Therapy; Drug · Radiation
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pelvic Cancer
Interventions: Pelvic Exercise; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Copper Cu 64 PSMA I&T; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 43
States / cities: Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more

Conditions: Prostate Cancer
Interventions: three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy, Anti-androgen, luteinizing hormone-releasing hormone (LHRH) agonist or antagonist; Radiation · Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 2,590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 454
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 351 more

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: filgrastim, carboplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2007
U.S. locations: 2
States / cities: New York, New York

Conditions: Advanced Bulky Malignancies
Interventions: Spatially Fractioned Radiation Therapy, Treatment Group 1, Standard radiation; Radiation
Lead sponsor: Summa Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Invasive Bladder Cancer
Interventions: HIPEC; Procedure
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Cancer
Interventions: High Dose Brachytherapy, Stereostatic Body Radiation Therapy; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Gynecologic Oncological Pelvic/Abdominal Surgery
Interventions: atorvastatin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Renal Vascular Disease, Nutcracker Syndrome, Renal, Pelvic Trauma, Loin Pain-Hematuria Syndrome, Renal Tumor, Congestion, Venous
Interventions: Pre-Operative Information, Intra-Operative Data, Post-Operative Data (up to discharge), Short-Term Follow-Up Data; Procedure · Other
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: Stereotactic Ablative Radiotherapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sarcoma, Thoracic Cancer, Abdominal Cancer, Pelvic Cancer
Interventions: Stereotactic body radiotherapy, Research blood draw; Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

Pilot Study of Epoetin Alfa for Patients Having Abdominal or Pelvic Surgery for Cancer

GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries

A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma

Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

Prehabilitation for Pelvic Cancer: Changes in Setup Variability

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer

Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy

HIPEC After Radical Cystectomy for High Risk Bladder Cancer

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer

High-dose Periop Statins for Prevention of DVT

Renal Autotransplantation; Case Series

Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers